科美诊断：预计2025年年度净利润为4000万元~4800万元，同比减少62.23%~68.52%

Core Viewpoint - Company expects a significant decrease in net profit for 2025, projecting between RMB 40 million to 48 million, which represents a year-on-year decline of 62.23% to 68.52 due to industry pressures [1] Financial Performance - The anticipated decline in net profit is primarily attributed to the impact of centralized procurement in the in vitro diagnostic industry, leading to price pressures on the company's main products and a decrease in main business revenue [1] - The company reported a reduction in non-recurring gains such as government subsidies compared to the previous year [1] Strategic Initiatives - To enhance core competitiveness, the company maintains a high level of investment in product innovation [1] - The company adheres to a long-term operational philosophy of serving human health through leading technology and innovative products, leveraging its proprietary LiCA® technology platform [1] - The company is focused on a dual-driven strategy of import substitution and clinical interactive innovation to create high-cost performance clinical products [1] Future Outlook - The company plans to continue its innovation-driven development path, strengthen cost management, actively respond to industry changes, and steadily advance the construction of core competitiveness to achieve sustainable high-quality development [1]